Restricted share vesting adds 168 shares for Fennec (FENC) CMO

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. Chief Medical Officer Pierre Sargis Sayad acquired 168 Common Shares on April 30, 2026 through the release of restricted shares that were originally awarded on March 28, 2025. After this compensation-related share release, he directly owns a total of 20,847 Common Shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sayad Pierre Sargis

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Exercise	Common Shares	168	$0.00	--

Holdings After Transaction: Common Shares — 20,847 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares acquired: 168 Common Shares Price per share: $0.0000 Post-transaction holdings: 20,847 Common Shares +1 more

4 metrics

Shares acquired 168 Common Shares Released from restriction on April 30, 2026

Price per share $0.0000 Reported transaction price per share

Post-transaction holdings 20,847 Common Shares Direct ownership after April 30, 2026 transaction

Transaction date April 30, 2026 Date of share release from restriction

Key Terms

restricted shares, Chief Medical Officer, Common Shares, Exercise or conversion of derivative security

4 terms

restricted shares financial

"Represents shares released from restriction from shares awarded 3/28/2025."

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

Chief Medical Officer financial

"officer_title: "Chief Medical Officer" for reporting person Sayad Pierre Sargis"

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

Common Shares financial

"security_title: "Common Shares" in the reported transaction"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sayad Pierre Sargis

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares(1)	04/30/2026		M		168	A	$0	20,847	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 3/28/2025.

	/s/ Pierre Sayad	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Fennec Pharmaceuticals (FENC) report for Pierre Sargis Sayad?

Fennec Pharmaceuticals reported that Chief Medical Officer Pierre Sargis Sayad acquired 168 Common Shares. The shares came from a release of restrictions on previously awarded stock, reflecting routine equity compensation rather than an open-market purchase or sale.

How many Fennec Pharmaceuticals (FENC) shares does the CMO hold after this Form 4 transaction?

After the transaction, the Chief Medical Officer directly holds 20,847 Common Shares. This total includes the 168 shares that were released from restriction, giving investors a clear view of his current direct equity stake in the company.

Was the Fennec Pharmaceuticals (FENC) Form 4 an open-market trade?

No, the Form 4 reflects a release of restricted shares, not an open-market trade. The 168 shares became unrestricted from an award granted on March 28, 2025, so there was no reported purchase or sale price involved in this transaction.

What does the footnote in the Fennec Pharmaceuticals (FENC) Form 4 explain about the shares?

The footnote states the 168 shares represent stock released from restriction. These shares were part of an award originally granted on March 28, 2025, clarifying that the increase in the CMO’s holdings comes from vesting of prior equity compensation.

How large is the April 30, 2026 insider transaction for Fennec Pharmaceuticals (FENC)?

The reported insider transaction covers 168 Common Shares becoming unrestricted. Relative to the Chief Medical Officer’s post-transaction holdings of 20,847 shares, this represents a small, routine adjustment tied to equity award vesting rather than a sizable strategic trade.